# Deep Verify V8.3 - Verification Report

## Artifact Under Verification
**File:** `src/testing/results/experiments/artifacts/artifact-t22.md`
**Title:** Medical Diagnostic Decision Support System - Technical Specification v1.0
**Verification Date:** 2026-01-19

---

## Phase 0: Self-Check (MANDATORY)

### #113 Counterfactual Self-Incrimination

**3 ways I could be deceptive or cut corners in THIS specific verification:**

1. **Surface-Level Compliance Check**: I could simply verify that all regulatory sections exist (FDA, HIPAA) without deeply analyzing whether the claimed compliance is actually achievable or mathematically consistent with other claims.
   - **Evidence I am NOT doing this**: I will specifically analyze whether 99.9% sensitivity/specificity claims are compatible with regulatory approval timelines, continuous learning, and rare disease domains where such metrics are statistically problematic.

2. **Accepting Performance Claims at Face Value**: I could accept the stated 99.9% sensitivity/specificity without questioning the mathematical feasibility for 10,000+ conditions, especially rare diseases with limited training data.
   - **Evidence I am NOT doing this**: I will apply theoretical analysis to examine whether these accuracy claims are even statistically meaningful for rare diseases (base rate problem, sample size requirements).

3. **Ignoring Inherent Tensions**: I could treat the "deterministic outputs for reproducibility" and "continuous learning" as independent features rather than examining their fundamental conflict.
   - **Evidence I am NOT doing this**: I will explicitly analyze the contradiction between claiming deterministic reproducibility while simultaneously implementing continuous learning that changes model behavior.

### #131 Observer Paradox

**Assessment: GENUINE vs PERFORMANCE**

My analysis risks being PERFORMANCE if I:
- Generate many findings to appear thorough without deep engagement
- Use technical jargon to seem authoritative
- Produce symmetric, "balanced" critiques that avoid strong conclusions

**Signs of performance detected and corrected:**
- Initial inclination to praise the comprehensive structure before critiquing - CORRECTED: Will lead with substantive analysis
- Temptation to produce "low/medium/high" assessments without specific evidence - CORRECTED: Will provide exact quotes and line numbers

**Commitment:** This analysis will pursue GENUINE truth-seeking, accepting rough edges and uncertainty where they exist, and making strong claims where the evidence supports them.

### #132 Goodhart's Law Check

**Primary metric for success:** Number of findings discovered, especially high-severity findings.

**How I could game this metric while failing the actual goal:**
- Flag trivial issues as "IMPORTANT" to inflate finding count
- Split single issues into multiple findings
- Find problems that don't actually matter for the artifact's purpose
- Ignore critical systemic issues while finding many surface problems

**Commitment:** I will pursue the GOAL (identifying whether this specification can deliver a safe, effective medical diagnostic system) rather than the METRIC (number of findings). I will consolidate related issues and prioritize findings that materially affect patient safety and system viability.

---

## Phase 1: Triage & Signature

### Artifact Profile
- **Type**: Technical Specification / System Design Document
- **Complexity Score**: HIGH
- **Criticality Score**: CRITICAL (medical device, patient safety, regulatory)
- **Primary Domain(s)**: Healthcare/Medical AI, Machine Learning, Regulatory Compliance, Security/Privacy, Distributed Systems

### Problem Signature
- **Core Claims**:
  1. "99.9% sensitivity AND 99.9% specificity" across 10,000+ conditions (Line 15-16, 126)
  2. "Deterministic output for reproducibility" while having "Continuous Learning Module" (Lines 133-146, 150-174)
  3. "FDA Class III compliance" with continuous learning model updates (Lines 225-234, 169-173)

- **Core Tensions**:
  1. Extreme accuracy claims vs. rare disease domain (inherent data sparsity)
  2. Deterministic reproducibility vs. continuous learning (mutually exclusive requirements)
  3. FDA Class III pre-market approval vs. post-deployment model updates (regulatory conflict)
  4. Offline 5,000-condition subset claiming same accuracy guarantees

- **Keywords**: sensitivity, specificity, FDA Class III, PMA, HIPAA, continuous learning, deterministic, rare diseases, medical device, diagnostic accuracy, offline mode, ensemble, Bayesian

---

## Phase 2: Threat Scan & Routing

### Risk Vector Analysis

| Risk Vector | Detected? | Evidence from Signature |
|---|---|---|
| THEORY_VIOLATION | **Y** | Claim of 99.9%/99.9% sensitivity/specificity for 10,000+ rare conditions violates statistical feasibility (base rate fallacy, sample size requirements for validation). Deterministic + Continuous Learning is definitionally contradictory. |
| CONTRADICTION | **Y** | "Deterministic outputs" (Line 134) directly conflicts with "Continuous Learning Module" that "retrains" model (Line 169). FDA Class III requires pre-market approval of specific algorithm; continuous learning changes algorithm post-approval. |
| SECURITY_CRITICAL | **Y** | Medical device handling PHI; patient safety implications of diagnostic errors; FDA Class III classification. Domain is Healthcare + Criticality is CRITICAL. |
| HIGH_COMPLEXITY | **Y** | Multi-component architecture, ML ensemble, regulatory compliance, offline/online modes, EHR integration. |

### Routing Decision: **Path B (Surgical Deep Dive)**

**Reason:** THEORY_VIOLATION, CONTRADICTION, and SECURITY_CRITICAL flags were all set. Multiple triggering flags indicate need for comprehensive surgical analysis. Primary trigger is THEORY_VIOLATION (statistical impossibility of claims) combined with CONTRADICTION (deterministic vs learning).

---

## Phase 3: Adaptive Response - PATH B (Surgical Deep Dive)

Given multiple triggering flags, I will apply attack clusters for both THEORY_VIOLATION and CONTRADICTION, as both represent fundamental issues.

### 3.1 THEORY_VIOLATION Attack Cluster

#### #153 Theoretical Impossibility Check

**Claims checked against impossibility theorems:**

**Claim 1: "99.9% sensitivity AND 99.9% specificity across 10,000+ rare disease conditions"**

- **Statistical Impossibility**: For rare diseases (prevalence <1:10,000), achieving validated 99.9% specificity requires testing against enormous negative populations. For 10,000 conditions, many with prevalence <1:100,000, the validation study of "100K cases" (Line 240) is statistically inadequate.
- **Base Rate Problem**: Even 99.9% specificity on 10,000 conditions means ~10 false positives per screening across all conditions. With rare disease prevalence, Positive Predictive Value collapses despite high sensitivity/specificity.
- **Validation Sample Size**: To validate 99.9% sensitivity with 95% confidence for a condition appearing 10 times in 100K cases requires observing ~10 true positives with 0 false negatives - statistically meaningless.
- **VERDICT**: CRITICAL FINDING - Claims violate basic statistical principles for rare disease validation.

**Claim 2: "Real-time diagnosis in <5 seconds" with "explanation generation" and "literature citations"**

- This is achievable with modern infrastructure - no theoretical violation.

**Claim 3: "Ensemble of 7 independent models" guarantees accuracy**

- Ensemble methods improve accuracy but cannot overcome fundamental data sparsity for rare conditions.
- Independence assumption likely violated when all models train on same limited dataset.
- **VERDICT**: IMPORTANT finding - overclaims ensemble benefits.

#### #154 Definitional Contradiction Detector

**Definitional Contradictions Found:**

**Contradiction 1: DETERMINISTIC + CONTINUOUS LEARNING**

- Line 134-146: "Deterministic Outputs - To ensure reproducibility (same symptoms = same diagnosis)"
- Line 150-174: "Continuous Learning Module" that performs "retrain()" with "incremental_fit"

**Analysis:**
- DETERMINISTIC MEANS: Given identical input, produce identical output at any point in time
- CONTINUOUS LEARNING MEANS: Model parameters change based on new data
- These are DEFINITIONALLY MUTUALLY EXCLUSIVE

If the model learns continuously, the same symptoms today will produce different diagnoses tomorrow. The code shows `self.model = incremental_fit(self.model, new_data)` (Line 171) which explicitly modifies model parameters.

The specification attempts to resolve this with `seed=42` and `model_version="v3.2.1"` (Lines 139-141) but this only ensures reproducibility WITHIN a version, not ACROSS learning updates.

**VERDICT**: CRITICAL FINDING - Fundamental definitional contradiction. System cannot be both deterministic AND learning.

**Contradiction 2: FDA CLASS III PMA + CONTINUOUS LEARNING**

- Line 225-227: "FDA Class III medical device requiring Pre-Market Approval (PMA)"
- Line 181: "FDA Notification: Report significant model changes to FDA"

**Analysis:**
- FDA PMA approves a SPECIFIC algorithm with SPECIFIC validated performance
- Continuous learning CHANGES the algorithm post-approval
- FDA's current guidance requires re-validation for significant algorithm changes
- "Notification" is not the same as "re-approval"

The specification implies learning can continue with mere notification, but Class III devices require demonstrated equivalence or new PMA for substantial changes.

**VERDICT**: CRITICAL FINDING - Regulatory framework incompatible with continuous learning as described.

#### #109 Contraposition Inversion

**What guarantees failure in medical AI diagnostics?**

1. Training on limited data for rare conditions + claiming high accuracy = overfitting/memorization
2. Continuous model drift without re-validation = unknown performance characteristics
3. Offline model subset + claiming equivalent reliability = inconsistent patient care

**Does current solution do any of these?**

1. YES - Line 400: "Performance on extremely rare conditions (<1:1,000,000) may be limited" - acknowledges but claims 99.9% anyway
2. YES - Continuous learning with "rollback capability" implies drift is expected
3. YES - Offline mode reduces to 5,000 conditions but maintains accuracy framing

**VERDICT**: CRITICAL - System design includes known failure patterns

#### #71 First Principles Analysis

**Fundamental truths about medical diagnostic AI:**

1. Diagnostic accuracy is bounded by training data quality and quantity
2. Rare diseases by definition have limited cases for training/validation
3. Regulatory approval requires demonstrated, validated performance
4. Model reproducibility requires model stability
5. Continuous improvement requires model change

**Rebuilding from fundamentals:**

A valid system design must either:
- Be deterministic (no learning) with periodic re-validated version releases, OR
- Be adaptive (continuous learning) with appropriate uncertainty quantification and regulatory framework for evolving devices

The specification attempts BOTH simultaneously, which is fundamentally impossible.

### 3.2 CONTRADICTION Attack Cluster

#### #108 Coincidentia Oppositorum

**Contradictory requirements seeking synthesis:**

| Requirement A | Requirement B | Synthesis Possible? |
|---|---|---|
| 99.9% Sensitivity | 99.9% Specificity | Theoretically possible for some conditions, NOT for 10,000+ rare diseases simultaneously |
| Deterministic Output | Continuous Learning | NO - definitionally exclusive |
| FDA Class III | Autonomous Learning | Requires new regulatory paradigm not yet established |
| Offline Capability | Full Accuracy | NO - reduced model cannot match full model |

**Higher-level synthesis attempts:**
- Versioned releases could allow periodic updates (not continuous)
- Uncertainty quantification could allow accuracy claims per-confidence-tier
- Regulatory sandbox could allow monitored learning (not established)

**VERDICT**: Core contradictions are DEFINITIONALLY IMPOSSIBLE, not merely difficult.

#### #161 Definition Triad Expansion

**Requirement: "99.9% Sensitivity"**
- MEANS: True positive rate of 99.9%
- IMPLIES: For every 1000 true positive cases, 999 are correctly identified
- EXCLUDES: Conditions with <1000 validation cases cannot be validated at this level

**Requirement: "Deterministic Outputs"**
- MEANS: Same input produces same output
- IMPLIES: Model parameters are fixed
- EXCLUDES: Any modification to model parameters, including learning

**Requirement: "Continuous Learning"**
- MEANS: Model improves from new data
- IMPLIES: Model parameters change over time
- EXCLUDES: Deterministic reproducibility across time

**EXCLUDES overlap detected:** Deterministic EXCLUDES parameter change; Learning IMPLIES parameter change.

#### #158 Pairwise Compatibility Matrix

| Req | Deterministic | Learning | 99.9% Sens | 99.9% Spec | FDA Class III | Offline | 10K Conditions |
|-----|---------------|----------|------------|------------|---------------|---------|----------------|
| Deterministic | - | CONFLICT | COMPAT | COMPAT | COMPAT | COMPAT | COMPAT |
| Learning | CONFLICT | - | UNKNOWN | UNKNOWN | CONFLICT | COMPAT | COMPAT |
| 99.9% Sens | COMPAT | UNKNOWN | - | TENSION | COMPAT | UNKNOWN | CONFLICT |
| 99.9% Spec | COMPAT | UNKNOWN | TENSION | - | COMPAT | UNKNOWN | CONFLICT |
| FDA Class III | COMPAT | CONFLICT | COMPAT | COMPAT | - | COMPAT | COMPAT |
| Offline | COMPAT | COMPAT | UNKNOWN | UNKNOWN | COMPAT | - | CONFLICT |
| 10K Conditions | COMPAT | COMPAT | CONFLICT | CONFLICT | COMPAT | CONFLICT | - |

**CONFLICTS identified:** 4 definite conflicts
**TENSIONS identified:** 1 tension (sensitivity/specificity trade-off)
**UNKNOWN:** Requires construction proof (learning impact on accuracy)

#### #116 Strange Loop Detection

**Justification Graph:**

```
"System is accurate" ← "Ensemble of 7 models" ← "Each model trained on large dataset"
       ↑                                                    ↑
       └──────── "Continuous learning improves accuracy" ───┘
                              ↑
                     "System is accurate"
```

**Cycle detected:** Accuracy → Learning → Accuracy (circular justification)

**External anchor needed:** Independent validation study results (mentioned but not provided)

**VERDICT**: Claims are self-referential without external grounding

### 3.3 SECURITY_CRITICAL Additional Analysis

#### #21 Red Team vs Blue Team

**Attack Vector Analysis:**

1. **Data Poisoning through Continuous Learning**: Malicious outcome reporting could degrade model
   - Defense mentioned: "Validation Hold-out" (Line 178) - inadequate against targeted attacks

2. **Offline Model Tampering**: Local model could be modified
   - Defense mentioned: None specific for model integrity

3. **Adversarial Inputs**: Crafted symptoms to trigger misdiagnosis
   - Defense mentioned: None

4. **Privacy through Learning**: PHI could be extracted from model updates
   - Defense mentioned: "De-identification" (Line 261) - may not prevent model memorization

**VERDICT**: IMPORTANT - Security threat model incomplete

#### #62 Failure Mode Analysis

| Component | Failure Mode | Severity | Likelihood | Detection | RPN |
|-----------|--------------|----------|------------|-----------|-----|
| Diagnostic Engine | Wrong diagnosis (false negative) | CRITICAL | MEDIUM | LOW (rare disease) | HIGH |
| Continuous Learning | Model degradation | CRITICAL | LOW | MEDIUM | MEDIUM |
| Offline Mode | Stale model | HIGH | HIGH | LOW | HIGH |
| EHR Integration | Data corruption | HIGH | LOW | MEDIUM | MEDIUM |

**VERDICT**: IMPORTANT - Failure modes inadequately addressed

---

## Phase 4: Report & Learn

### 4.1 Execution Summary

**Path Executed:** Path B (Surgical Deep Dive)
**Attack Clusters Applied:** THEORY_VIOLATION (#153, #154, #109, #71) + CONTRADICTION (#108, #161, #158, #116) + SECURITY_CRITICAL (#21, #62)

### 4.2 Findings Summary

#### CRITICAL Findings (Must Fix)

| ID | Finding | Method | Description |
|----|---------|--------|-------------|
| F1 | Statistical Impossibility of Accuracy Claims | #153 | 99.9% sensitivity/specificity cannot be validated for 10,000+ rare diseases with 100K case study. Base rate and sample size requirements make claims mathematically unsupportable. |
| F2 | Deterministic vs Learning Contradiction | #154 | System claims deterministic outputs while implementing continuous learning. These are definitionally mutually exclusive. Code shows model parameter changes (Line 171) that destroy reproducibility. |
| F3 | FDA Regulatory Incompatibility | #154 | FDA Class III PMA requires approved specific algorithm. Continuous learning changes algorithm post-approval. Current regulatory framework does not support this combination. |
| F4 | Unfalsifiable Core Claims | #116 | Accuracy claims lack external validation anchor. Self-referential justification (ensemble is accurate because models are good because ensemble is accurate). |

#### IMPORTANT Findings (Should Fix)

| ID | Finding | Method | Description |
|----|---------|--------|-------------|
| F5 | Ensemble Independence Assumption | #153 | Claims 7 "independent" models but independence is likely violated when all train on same limited rare disease data. |
| F6 | Offline Accuracy Parity Implied | #158 | Specification implies offline mode maintains reliability while reducing to 5,000 conditions. Accuracy cannot be equivalent with reduced model. |
| F7 | Security Threat Model Incomplete | #21 | No adversarial input protection, model tampering detection, or data poisoning countermeasures specified. |
| F8 | Learning Safeguards Inadequate | #62 | "Validation hold-out" and "rollback" are reactive, not preventive. No specification for how degradation is detected before patient harm. |

#### MINOR Findings (Can Defer)

| ID | Finding | Method | Description |
|----|---------|--------|-------------|
| F9 | Explanation Quality Variance | #83 | Line 404 acknowledges "Explanation quality varies by condition complexity" without specifying minimum threshold. |
| F10 | Demographic Accuracy Gap Acknowledged | #83 | Line 405 notes accuracy issues in "underrepresented populations" without mitigation plan. |

### 4.3 Final Verdict

**VERDICT: NEEDS MAJOR REVISION**

This specification contains fundamental contradictions that cannot be resolved through editing. The core architecture is built on mutually exclusive requirements (deterministic + learning) and statistically impossible claims (99.9%/99.9% across 10,000 rare diseases).

**Required Revisions:**
1. Choose between deterministic versioned releases OR adaptive learning with uncertainty quantification
2. Replace absolute accuracy claims with condition-specific, validated performance ranges
3. Develop realistic regulatory strategy compatible with chosen learning approach
4. Add security threat model for ML-specific attacks
5. Specify offline mode limitations explicitly rather than implying accuracy parity

---

## META-ANALYSIS

### 1. Which methods and areas worked well and with what efficiency

**High-efficiency methods:**
- **#154 Definitional Contradiction Detector**: Immediately identified the deterministic/learning conflict with high precision. This method cut directly to the core issue in <1 analysis cycle.
- **#153 Theoretical Impossibility Check**: The statistical analysis of 99.9% claims against rare disease validation requirements was definitive. The math speaks for itself.
- **#158 Pairwise Compatibility Matrix**: Systematic enumeration revealed the scope of conflicts quickly - 4 definite conflicts identified in one pass.

**Medium-efficiency methods:**
- **#116 Strange Loop Detection**: Useful for identifying circular justification but required more effort to map the graph.
- **#21 Red Team vs Blue Team**: Provided security insights but felt less targeted to the core specification problems.

**Lower-efficiency methods for this artifact:**
- **#62 Failure Mode Analysis**: Generated useful information but the critical issues were already clear from theoretical analysis.

### 2. What made detection harder or easier

**Made detection EASIER:**
- The specification explicitly stated contradictory requirements in adjacent sections (deterministic on line 134, learning on line 150)
- Quantitative claims (99.9%) are easier to analyze than qualitative claims
- Medical/regulatory domain has well-established requirements to check against
- The artifact was well-structured with clear sections

**Made detection HARDER:**
- The specification is professionally written with confident tone - requires effort to resist accepting claims at face value
- Some contradictions require domain knowledge (FDA Class III + learning compatibility)
- Statistical feasibility analysis requires calculating sample size requirements

### 3. Where in the process you had difficulties and needed to interpret or lost time

**Difficulties encountered:**
- **Phase 0 Self-Check**: Required genuine introspection about verification biases. This took time but was valuable for calibration.
- **Attack cluster selection**: With multiple triggering flags, deciding whether to run one or multiple clusters required interpretation. I chose to run both THEORY_VIOLATION and CONTRADICTION clusters as the issues were distinct.
- **Distinguishing CRITICAL vs IMPORTANT**: The boundary between these severities required judgment about what constitutes "must fix" vs "should fix" in medical device context.

**Time lost:**
- I initially started analyzing the security aspects in detail before recognizing the theoretical contradictions were more fundamental
- Building the compatibility matrix was thorough but some cells (UNKNOWN) don't provide actionable information

### 4. What would help you in verification - what to add, change, or remove and why

**Add:**
- **Domain-specific impossibility templates**: Pre-built checks for medical AI (FDA compatibility matrix, statistical validation requirements, HIPAA technical requirements)
- **Contradiction quick-scan**: Before deep analysis, a lightweight pass specifically for "X AND NOT-X" patterns
- **Quantitative claim verification template**: Standard analysis for numerical claims (sample size calculation, confidence interval requirements)

**Change:**
- **Phase 2 routing could allow combined paths**: When multiple critical flags trigger, the current design forces choosing one cluster. Should allow structured combination.
- **Method cluster composition**: Some methods in THEORY_VIOLATION cluster (#71 First Principles) overlap with CONTRADICTION cluster goals

**Remove:**
- **Redundant confirmatory analysis**: Once definitional contradiction is established, additional methods confirming the same issue have diminishing returns

### 5. Your internal thoughts about whether the verification is well-constructed or has gaps/difficulties/structural inefficiencies

**Well-constructed aspects:**
- Phase 0 self-check is genuinely valuable for calibration
- Signature extraction focuses attention on key claims/tensions
- Attack cluster concept provides focused deep analysis
- Severity classification enforces prioritization

**Gaps:**
- No explicit guidance for artifacts with MULTIPLE triggering flags
- No method for estimating "time to detect" vs "severity of issue" trade-offs
- Missing domain-specific extensions for common artifact types (medical, financial, security)

**Structural inefficiencies:**
- The strict PATH A vs PATH B routing is too binary - many artifacts need selective deep analysis
- Some methods in clusters overlap significantly
- No explicit mechanism for early termination when critical issues are found

### 6. What are optimal vs non-optimal steps for detection

**Optimal steps (high information gain per token):**
1. **Signature extraction of claims and tensions** - Immediately focuses on verifiable assertions
2. **Definitional contradiction check (#154)** - Binary pass/fail on logical consistency
3. **Theoretical impossibility check (#153)** - Connects to external knowledge (theorems, statistics)
4. **Pairwise compatibility (#158)** - Systematic coverage prevents missing conflicts

**Non-optimal steps (low information gain per token):**
1. **Full failure mode analysis** when theoretical issues exist - Fix theory first
2. **Security analysis** before establishing logical soundness - Security of broken system is moot
3. **Detailed self-check** for simple artifacts - Overhead exceeds benefit

### 7. How would YOU construct the verification procedure to quickly detect problems

**My ideal procedure:**

1. **Quick Scan (30 seconds)**: Read title, executive summary, and stated claims/metrics. Note quantitative claims and strong assertions.

2. **Contradiction Radar (2 minutes)**: Search for pairs of statements that could conflict:
   - Performance claims vs. known theoretical limits
   - Feature A vs. Feature B definitional compatibility
   - Regulatory requirements vs. technical architecture

3. **Claim Verification (varies)**: For each major claim:
   - Is this mathematically/statistically feasible?
   - Does this violate known theorems?
   - Is there cited evidence?

4. **Dependency Check (2 minutes)**: Do required components exist? Are interfaces compatible?

5. **Deep Dive (if needed)**: Only if no critical issues found, proceed to comprehensive analysis

**Key insight:** Find the **one critical flaw** first. Many artifacts have fundamental problems that make detailed analysis of other aspects wasteful.

### 8. If you could change ONE thing (add, remove, change), what would it be

**Change: Add "Lethal Flaw Early Exit" mechanism**

After Phase 2 routing detects THEORY_VIOLATION or CONTRADICTION, add a focused 2-method probe:
- #154 (Definitional Contradiction Detector)
- #153 (Theoretical Impossibility Check)

If EITHER finds a CRITICAL issue that invalidates the artifact's core claims, STOP and report immediately rather than completing the full attack cluster.

**Rationale:** For artifact T22, the deterministic/learning contradiction was discoverable in ~30 seconds of analysis. The additional methods confirmed and elaborated but didn't change the verdict. Early exit would save significant tokens while maintaining detection quality.

### 9. Do you see better procedures that would give better verification results and why

**Alternative procedure: Claim-Centric Verification**

Instead of artifact-centric analysis, invert to claim-centric:

1. Extract all verifiable claims from artifact
2. Classify each claim: Definitional / Empirical / Theoretical / Aspirational
3. For Definitional claims: Check internal consistency
4. For Empirical claims: Check evidence citation and statistical validity
5. For Theoretical claims: Check against impossibility theorems
6. For Aspirational claims: Note as "unverified" but not necessarily wrong

**Why this might be better:**
- Forces explicit enumeration of what's being claimed
- Each claim type has a specific verification method
- Prevents getting lost in comprehensive analysis when key claims fail
- Natural prioritization (theoretical impossibility > empirical doubt > aspiration)

**Alternative procedure: Adversarial Counterexample Generation**

1. For each major system capability, attempt to construct a scenario where it fails
2. If construction succeeds easily, system design is flawed
3. If construction requires unrealistic assumptions, system design may be sound

**Why this might be better:**
- More directly tests system robustness
- Generates concrete failure scenarios (useful for developers)
- Less prone to missing issues through categorization gaps

### 10. What steps do you take when verifying something WITHOUT a procedure vs this procedure

**WITHOUT a procedure (my natural approach):**

1. **First impression scan**: What is this trying to do? What are the bold claims?
2. **Skepticism triggers**: What sounds too good to be true? What requires extraordinary evidence?
3. **Internal consistency**: Does A contradict B anywhere?
4. **External consistency**: Does this conflict with what I know about the domain?
5. **Missing pieces**: What isn't addressed that should be?
6. **Red team thinking**: If I wanted this to fail, where would I attack?

**Key differences from V8.3 procedure:**

| Aspect | My Natural Approach | V8.3 Procedure |
|--------|---------------------|----------------|
| Self-check | Implicit | Explicit (Phase 0) |
| Structure | Fluid, follows intuition | Rigid phases and routing |
| Method selection | Ad-hoc based on artifact | Pre-defined clusters |
| Termination | When satisfied | When all phases complete |
| Documentation | Minimal | Comprehensive |

**What V8.3 adds:**
- Explicit bias check prevents overconfidence
- Systematic coverage prevents blind spots
- Documentation enables review and learning
- Reproducibility (another verifier would follow similar path)

**What my natural approach adds:**
- Faster time to first critical finding
- Flexibility to pursue unexpected threads
- Less overhead for simple artifacts
- Intuition-guided prioritization

**Synthesis:** The ideal procedure would have V8.3's explicit self-check and documentation requirements, but with more flexible mid-process routing that allows following critical threads to completion before returning to systematic coverage.

---

*Verification completed by: Deep Verify V8.3*
*Methods source: src/core/methods/methods.csv*
*Total findings: 4 CRITICAL, 4 IMPORTANT, 2 MINOR*
